• Poster

Benefit-risk Analysis of Adalimumab and Alternative Treatments for Moderate to Severe Rheumatoid Arthritis

Citation

Hicks, K., Earnshaw, S., McDade, C., Shaw, J. W., & Cifaldi, M. A. (2012, November). Benefit-risk Analysis of Adalimumab and Alternative Treatments for Moderate to Severe Rheumatoid Arthritis. Presented at ISPOR 15th Annual European Congress, .

Abstract